The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis
Open accessAbstract
OBJECTIVES: Skin fibrosis mediated by activated dermal fibroblasts is a hallmark of systemic sclerosis (SSc), especially in the subset of patients with diffuse disease. Transforming growth factor-beta (TGFβ) and interleukin-6 (IL-6) are key candidate mediators in SSc. Our aim was to elucidate the specific effect of IL-6 pathway blockade on the biology of SSc fibroblasts in vivo by using samples from a unique clinical experiment-the faSScinate study-in which patients with SSc were treated for 24 weeks with tocilizumab (TCZ), an IL-6 receptor-α inhibitor. METHODS: We analysed the molecular, functional and genomic characteristics of explant fibroblasts cultured from matched skin biopsy samples collected at baseline and at week 24 from 12 patients receiving placebo (n=6) or TCZ (n=6) and compared these with matched healthy control fibroblast strains. RESULTS: The hallmark functional and molecular-activated phenotype was defined in SSc samples and was stable over 24 weeks in placebo-treated cases. RNA sequencing analysis robustly defined key dysregulated pathways likely to drive SSc fibroblast activation in vivo. Treatment with TCZ for 24 weeks profoundly altered the biological characteristics of explant dermal fibroblasts by normalising functional properties and reversing gene expression profiles dominated by TGFβ-regulated genes and molecular pathways. CONCLUSIONS: We demonstrated the exceptional value of using explant dermal fibroblast cultures from a well-designed trial in SSc to provide a molecular framework linking IL-6 to key profibrotic pathways. The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. TRIAL REGISTRATION NUMBER: NCT01532869; Post-results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, in vitro, (myo)fibroblasts obtained from SSc patients produce more extracellular matrix molecules such as collagen type I than those of healthy controls, and their migratory and contractile properties are also increased (19, 98).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [98]
In the citing paper
“Tocilizumab is a humanized antibody directed against the IL-6 receptor and currently enrolled in a phase III trial for SSc therapy (98).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [98]
In the citing paper
“Strikingly, many TGFβ signaling related genes, together with cell contractility pathways, were downregulated to a level similar to normal expression levels (98).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [98]
In the citing paper
“Furthermore, a large effect between the tocilizumab and placebo treated groups was observed on gene expression profile; in the placebo group, gene expression was not significantly altered over 24 weeks, whereas in the tocilizumab treated group 2,136 genes were significantly differentially expressed.”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [98]
In the citing paper
“Treatment with tocilizumab for 24 weeks decreased fibroblast protein production, migration and contractility compared to baseline (98).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Self-citationEdlund, S., Landström, M., Heldin, C.-H., & Aspenström, P. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-08-0398 · Cited by 418
Shi-Wen, X., Chen, Y., Denton, C. P., Eastwood, M., Renzoni, E. A., Bou-Gharios, G., Pearson, J. D., Dashwood, M., du Bois, R. M., Black, C. M., et al. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-12-0902 · Cited by 356
Self-citationChakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
Ma, F., Li, Y., Jia, L., Han, Y., Cheng, J., Li, H., Qi, Y., & Du, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035144 · Cited by 271
Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro
Sriram, G., Bigliardi, P. L., & Bigliardi-Qi, M. (2015) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2015.08.001 · Cited by 269
De Lauretis, A., Sestini, P., Pantelidis, P., Hoyles, R., Hansell, D. M., Goh, N. S. L., Zappala, C. J., Visca, D., Maher, T. M., Denton, C. P., et al. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120725 · Cited by 263
Self-citationO'Reilly, S., Ciechomska, M., Cant, R., & van Laar, J. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545822 · Cited by 258
Cited by
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30318-0 · Cited by 662
Self-citationThe Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing
Johnson, B. Z., Stevenson, A. W., Prêle, C. M., Fear, M. W., & Wood, F. M. (2020) · Biomedicines · doi:10.3390/biomedicines8050101 · Cited by 529
Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer
Buechler, M. B., Fu, W., & Turley, S. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.021 · Cited by 494
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs
Wong, X. Y., Sena-Torralba, A., Álvarez-Diduk, R., Muthoosamy, K., & Merkoçi, A. (2020) · ACS Nano · doi:10.1021/acsnano.9b08133 · Cited by 363
Metadata
- Authors
- Denton, C. P., Ong, V. H., Xu, S., Chen-Harris, H., Modrusan, Z., Lafyatis, R., Khanna, D., Jahreis, A., Siegel, J., & Sornasse, T.
- Affiliations
- The Royal Free Hospital (GB)
- Genentech (US)
- University of Pittsburgh Medical Center (US)
- University of Michigan (US)
- Corresponding author
- Denton, Christopher P
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 77
- Issue
- 9
- Pages
- 1362-1371
- ISSN
- 0003-4967 (ISSN-L)
- PMC
- PMC6104680
- OpenAlex
- W2806476436
- Cited by
- 166
- References
- 41
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 17 · 2023: 35 · 2022: 18 · 2021: 29 · 2020: 22 · 2019: 13 · 2018: 3
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- systemic sclerosis, interleukin-6, IL-6 receptor inhibition, tocilizumab, TGF-beta, dermal fibroblasts, skin fibrosis, fibroblast activation, gene expression profiling, therapeutic target
- MeSH terms
- Adult, Biopsy, Cells, Cultured, Double-Blind Method, Female, Fibroblasts, Fibrosis, Gene Expression Regulation, Humans, Immunosuppressive Agents, Male, Middle Aged, Scleroderma, Systemic, Skin, Signal Transduction, Interleukin-6, Transforming Growth Factor beta, Receptors, Interleukin-6, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. https://app.cochat.ai/papers/10.1136/annrheumdis-2018-213031
- The paper
- Denton, C. P., Ong, V. H., Xu, S., Chen-Harris, H., Modrusan, Z., Lafyatis, R., Khanna, D., Jahreis, A., Siegel, J., & Sornasse, T. (2018). Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-213031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.